Q1 2026 13F · SEC CIK 2006045
SymBiosis Capital Partners, LLC
Hedge fundFiled 2026-05-12 for Q1 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $52.8M
- Reported positions
- 6
- Holdings vs S&P 500, 3 yrs
- —
- Average holding period
- 2 qtrs
SymBiosis Capital Partners, LLC is a hedge fund that reported 6 positions worth $52.8M in its Q1 2026 13F, filed 2026-05-12. Its largest holdings were Evommune Inc (EVMN, 55.8%), Inventiva SA (IVA, 24.8%), Wave Life Sciences Ltd (WVE, 10.3%).
SymBiosis Capital Partners, LLC holdings all 6 positions.
Weights are shares of the filer's total reported 13F value, compared with Q4 2025. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| EVMNEvommune Inc | 55.8% | +0.0% | $29.4M |
| IVAInventiva SA | 24.8% | -9.5% | $13.1M |
| WVEWave Life Sciences Ltd | 10.3% | — | $5.4M |
| RANIRani Therapeutics Holdings Inc | 5.1% | -41.8% | $2.7M |
| CLNNClene Inc | 4.0% | -44.0% | $2.1M |
| SRZNWSurrozen Inc | 0.0% | +0.0% | $2K |
What SymBiosis Capital Partners, LLC bought and sold in Q1 2026, against Q4 2025.
New positions
- WVE Wave Life Sciences Ltd10.3% of 13F
Added to
No position grew by more than 5%.
Reduced
- CLNN Clene Inc-44.0% shares
- RANI Rani Therapeutics Holdings Inc-41.8% shares
- IVA Inventiva SA-9.5% shares
Sold out
- VSTM Verastem Incwas 14.1%
- AMPG Amplitech Group Incwas 12.1%
- PGEN Precigen Incwas 11.5%
- NUVB Nuvation Bio Incwas 10.2%
- AARD Aardvark Therapeutics Incwas 5.7%
- GBIO Generation Bio Cowas 3.5%
Share counts compared with the Q4 2025 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- —
- 3 years
- —
- 5 years
- —
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q1 2026 | $52.8M | 6 |
| Q4 2025 | $109.5M | 11 |
Questions about SymBiosis Capital Partners, LLC's portfolio
What stocks does SymBiosis Capital Partners, LLC own?
SymBiosis Capital Partners, LLC's latest 13F, for Q1 2026 and filed May 12, 2026, lists 6 positions worth $52.8M. The largest are Evommune Inc (EVMN) at 55.8%, Inventiva SA (IVA) at 24.8%, Wave Life Sciences Ltd (WVE) at 10.3%, Rani Therapeutics Holdings Inc (RANI) at 5.1% and Clene Inc (CLNN) at 4.0%.
What did SymBiosis Capital Partners, LLC buy last quarter?
In Q1 2026, SymBiosis Capital Partners, LLC added a new position in Wave Life Sciences Ltd (WVE), compared with its Q4 2025 filing.
What did SymBiosis Capital Partners, LLC sell last quarter?
In Q1 2026, SymBiosis Capital Partners, LLC sold all of Verastem Inc (VSTM), sold all of Amplitech Group Inc (AMPG), sold all of Precigen Inc (PGEN), sold all of Nuvation Bio Inc (NUVB), sold all of Aardvark Therapeutics Inc (AARD), Clene Inc (CLNN) (-44.0% shares), Rani Therapeutics Holdings Inc (RANI) (-41.8% shares) and Inventiva SA (IVA) (-9.5% shares), compared with its Q4 2025 filing.
When is SymBiosis Capital Partners, LLC's next 13F filing due?
13F filings are due 45 days after each quarter ends. SymBiosis Capital Partners, LLC's filing for the quarter ending Jun 30, 2026 was due by Aug 14, 2026; this page updates once it is processed.